Article

Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer

2022-09-26

Abstract excerpt

In advanced non-small cell lung cancer (NSCLC), response to immunotherapy is difficult to predict from pre-treatment information. Given the toxicity of immunotherapy and its financial burden on the healthcare system, we set out to identify patients for whom treatment is effective. To this end, we used mutational signatures from DNA mutations in pre-treatment tissue. Single base substitutions, doublet base substitu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 800cfbcc-a07f-5695-9e12-a3a90cc9f4da
DOI: 10.1101/2022.09.23.509152

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancerDOI 10.1101/2022.09.23.509152Read

Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer.Semantic proximity Read

Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancers.Semantic proximity Read

Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer.Semantic proximity Read

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.Semantic proximity Read

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Semantic proximity Read

Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations.Semantic proximity Read

The Impact of Smoking Status on the Genomic Landscape of Lung Squamous Cell CarcinomaSemantic proximity Read

Decoding circulating tumor DNA to identify durable benefit from immunotherapy in lung cancer.Semantic proximity Read

Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC.Semantic proximity Read

TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung Adenocarcinoma.Semantic proximity Read

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer.Semantic proximity Read

Therapeutic and prognostic insights from the analysis of cancer mutational signatures.Semantic proximity Read